Top NasdaqGS Healthcare Dividend Paying Companies
The healthcare sector has a higher prevalence of companies with sustainable competitive advantages compared to other sectors which implies it may continue generating robust excess returns. When the economy is struggling and cyclical companies begin showing signs of weakness, investors often try to put their money into defensive companies in an effort to protect their portfolio during a downturn. I’ve identify the following healthcare stocks paying high income, which may increase the value of your portfolio.
Meridian Bioscience, Inc. (NASDAQ:VIVO)
VIVO has a sizeable dividend yield of 3.46% and has a payout ratio of 97.81% . While VIVO’s dividend has decreased from $0.5 to $0.56 over the past 10 years, they’ve at least been paying consistently in that time. Meridian Bioscience is a strong prospect for its future growth, with analysts expecting the company’s earnings to increase by 54.61% over the next three years. Continue research on Meridian Bioscience here.
Owens & Minor, Inc. (NYSE:OMI)
OMI has a sumptuous dividend yield of 6.54% and is currently distributing 81.32% of profits to shareholders . OMI’s DPS have risen to $1.04 from $0.5332 over a 10 year period. The company has been a reliable payer too, not missing a payment during this time. If analysts predictions are right, Owens & Minor has some strong earnings growth on the short-term horizon with an expected increase in EPS of 37.67% over the next 12 months. More on Owens & Minor here.
Quest Diagnostics Incorporated (NYSE:DGX)
DGX has a good dividend yield of 2.07% and pays out 32.07% of its profit as dividends . In the case of DGX, they have increased their dividend per share from $0.4 to $2 so in the past 10 years. They have been dependable too, not missing a single payment in this time. More on Quest Diagnostics here.
For more solid dividend payers to add to your portfolio, you can use our free platform to explore our interactive list of top dividend payers.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
